This treatment gap, particularly in people with obesity and insulin resistance, could be at least partially overcome with GLP-1 and GIP/GLP-1 receptor agonists, as this clinical setting calls for weight loss (indirect anti-inflammatory action) and a potential direct anti-inflammatory action of these medications to reduce asthma exacerbations, possibly through some of the described mechanisms. This evidence concerns the gene GLP1R and asthma.